Guide 03 of 03
Cover
Understanding Addiction
Guide 03 of 03

Understanding Medication-Assisted Treatment

Three FDA-approved medications change outcomes for people with opioid use disorder. This guide explains what each one does, how it works, and what to expect during treatment.

3x
MAT reduces risk of overdose death by up to three times
FDA
Approved medications with decades of clinical evidence
Best
Outcomes: medication combined with counseling and support
Section 1 of 5
What Is MAT?

Medication-assisted treatment combines FDA-approved medication with counseling and support.

MAT is not simply taking a pill. It is a structured clinical approach that addresses the biological component of opioid use disorder while counseling and peer support address the behavioral and social dimensions.

When opioids are used repeatedly, the brain adapts in ways that make stopping without help extremely difficult. The medications used in MAT work at the brain's opioid receptors. They reduce cravings, prevent withdrawal, and block the euphoric effects of other opioids, which stabilizes the brain chemistry that addiction has disrupted.

Research consistently shows that people who receive MAT have better survival, retention in treatment, and long-term recovery outcomes than those who attempt abstinence-only approaches without medication.

"Medications for opioid use disorder are not a crutch. They are the treatment. Withholding them is like withholding insulin from a person with diabetes."

ASAM Opioid Use Disorder Patient Guide 2025
For drug courts and supervision programs

All three medications are FDA-approved treatments for opioid use disorder and may produce positive results on standard drug panels. Positive results from prescribed MAT medications are not evidence of illicit drug use and should be interpreted in clinical context.

Section 2 of 5
Buprenorphine

Buprenorphine is the most widely prescribed medication for opioid use disorder.

Buprenorphine is a partial opioid agonist. It activates the brain's opioid receptors enough to prevent withdrawal and reduce cravings without producing the intense euphoria of full agonists like heroin or oxycodone.

Buprenorphine
Brand names: Suboxone (with naloxone), Sublocade (injectable), Subutex, Brixia
Film or tablet under the tongue; monthly injectable also available
DEA Schedule III; prescribable by certified physicians and NPs in an office setting
Requires a dedicated buprenorphine immunoassay; will not appear on standard opiate screens
Typically 3 to 7 days in urine; longer with heavy use or low cutoff
The naloxone component in combination products (Suboxone) is added as a deterrent against injection misuse. When taken as directed sublingually, the naloxone has minimal effect. Norbuprenorphine, the primary metabolite, is also tested and helps verify consistent use.
Section 3 of 5
Methadone

Methadone has the longest track record in opioid use disorder treatment, with over 50 years of data.

Methadone is a full opioid agonist. At therapeutic doses it eliminates withdrawal symptoms and cravings without producing euphoria. It must be dispensed through federally certified opioid treatment programs (OTPs).

Methadone
Brand names: Methadose, Dolophine
Oral liquid or tablet; dispensed daily at an OTP clinic; take-home doses earned over time
DEA Schedule II; dispensed only through federally certified OTPs, not standard pharmacies
Requires a dedicated methadone immunoassay; will not appear on a standard opiate screen
Typically 3 to 5 days; EDDP (the primary metabolite) is co-tested to confirm ingestion
Methadone requires dose titration and careful monitoring, particularly during induction. QTc interval monitoring may be recommended. The OTP model provides daily structure and clinical contact, which has been shown to benefit many people in early recovery.
Section 4 of 5
Naltrexone

Naltrexone blocks opioid effects entirely. It is the only MAT medication with no opioid activity.

Naltrexone is an opioid antagonist. It binds tightly to opioid receptors without activating them, blocking any opioid from producing an effect. It has no abuse potential and is not a controlled substance.

Naltrexone
Brand names: Vivitrol (monthly injection), ReVia (oral tablet)
Monthly intramuscular injection (preferred) or daily oral tablet
Not a controlled substance; prescribable by any licensed provider
Not detected by standard opioid immunoassays; will not produce a positive result
Must be opioid-free for 7 to 10 days before starting; premature use causes severe withdrawal
Naltrexone is often the preferred option in settings that require complete abstinence from opioids, including some drug courts. Because it has no opioid activity, it does not produce physical dependence. However, if a dose is missed, opioid tolerance is lost, which increases overdose risk if the person returns to use.
Section 5 of 5
Common Myths and Resources

Common misconceptions about MAT that the evidence does not support.

Myth

"MAT is just trading one addiction for another."

Addiction is defined by compulsive use despite harm. People taking MAT as prescribed are not experiencing addiction. They are receiving treatment for a chronic disease. Dependence on a medication is not the same as addiction to a substance.

Myth

"You are not in real recovery if you are on medication."

ASAM, SAMHSA, and every major addiction medicine organization define recovery broadly to include individuals who are stable on MAT. Medication is a component of treatment, not a barrier to recovery.

Myth

"The goal should always be to taper off the medication."

For some people, indefinite maintenance is the most effective treatment. Research shows higher rates of return to use after tapering. Duration of treatment should be determined clinically, not by a predetermined timeline or program policy.

Myth

"A positive buprenorphine or methadone result means the person is using something they should not be."

A positive result for a prescribed MAT medication is expected and appropriate. It should be confirmed by the prescribing provider's records, not treated as evidence of a violation.


Find treatment

SAMHSA National Helpline

Free, confidential treatment referrals. Available 24/7, 365 days a year. English and Spanish.

1-800-662-4357

findtreatment.gov

Locate nearby MAT providers, OTPs, and treatment programs by zip code.

Find Treatment →

Start with Guide 01

New to this series? Guide 01 explains the biology of addiction and why treatment works.

Read Guide 01 →

Clinical Reference

Recommended Reading

For a comprehensive patient-facing overview of opioid use disorder treatment, see the ASAM Opioid Use Disorder Patient Guide 2025, published by the American Society of Addiction Medicine and Guideline Central.

This guide is for general educational purposes only and does not constitute medical advice. If you are experiencing a medical emergency, call 911. For substance use support, contact SAMHSA at 1-800-662-4357.

Stay Ahead of What's in the Supply

New Patient Alerts and clinical updates are announced in ToxSignal, the free clinical toxicology newsletter from ToxiPharm.

Educational content is for general informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for guidance specific to your situation.